Literature DB >> 22231760

Prostate cancer in 2011: Hitting old targets better and identifying new targets.

Yu Chen1, Howard I Scher.   

Abstract

Options to treat late-stage castration-resistant prostate cancer continued to increase in 2011, as three agents with different mechanisms of action prolonged life and a fourth reduced the morbidity of skeletal metastases. These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies.

Entities:  

Mesh：

Year:  2012        PMID： 22231760      PMCID： PMC5572096          DOI： 10.1038/nrclinonc.2011.213

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

Review 1.  Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.

Authors:  Roger Chou; Jennifer M Croswell; Tracy Dana; Christina Bougatsos; Ian Blazina; Rongwei Fu; Ken Gleitsmann; Helen C Koenig; Clarence Lam; Ashley Maltz; J Bruin Rugge; Kenneth Lin
Journal:  Ann Intern Med       Date:  2011-10-07       Impact factor: 25.391

2.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.

Authors:  Evan Y Yu; George Wilding; Edwin Posadas; Mitchell Gross; Stephane Culine; Christophe Massard; Michael J Morris; Gary Hudes; Fabio Calabrò; Shinta Cheng; Géralyn C Trudel; Prashni Paliwal; Cora N Sternberg
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531
  7 in total
  6 in total

1.  Prostate cancer biomarker: a key field to explore.

Authors:  Jianqing Lin; Hushan Yang; William K Kelly
Journal:  Asian J Androl       Date:  2013-02-25       Impact factor: 3.285

2.  Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.

Authors:  Jessica K Simmons; Wessel P Dirksen; Blake E Hildreth; Carlee Dorr; Christina Williams; Rachael Thomas; Matthew Breen; Ramiro E Toribio; Thomas J Rosol
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

3.  RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.

Authors:  Hyejin Cho; Tali Herzka; Wu Zheng; Jun Qi; John E Wilkinson; James E Bradner; Brian D Robinson; Mireia Castillo-Martin; Carlos Cordon-Cardo; Lloyd C Trotman
Journal:  Cancer Discov       Date:  2014-01-20       Impact factor: 39.397

4.  Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit.

Authors:  Fei Yang; Nicholas G Nickols; Benjamin C Li; Jerzy O Szablowski; Shari R Hamilton; Jordan L Meier; Chieh-Mei Wang; Peter B Dervan
Journal:  J Med Chem       Date:  2013-09-09       Impact factor: 7.446

5.  Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression.

Authors:  Kandice L Tessneer; Satish Pasula; Xiaofeng Cai; Yunzhou Dong; Xiaolei Liu; Lili Yu; Scott Hahn; John McManus; Yiyuan Chen; Baojun Chang; Hong Chen
Journal:  ISRN Oncol       Date:  2013-04-04

6.  Metastatic phenotype in CWR22 prostate cancer xenograft following castration.

Authors:  Steven J Seedhouse; Hayley C Affronti; Ellen Karasik; Bryan M Gillard; Gissou Azabdaftari; Dominic J Smiraglia; Barbara A Foster
Journal:  Prostate       Date:  2015-12-08       Impact factor: 4.104
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.